In vitro antibiotic susceptibility of initial pseudomonas aeruginosa isolates from united states cystic fibrosis patients

Journal of the Pediatric Infectious Diseases Society

Volumn 4, Issue 2, 2015, Pages 151-154

  VanDevanter, Donald R ^a   Dalfsen, Jill M Van ^b   Burns, Jane L ^b,c   Mayer Hamblett, Nicole ^c,d  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SEATTLE CHILDREN S HOSPITAL   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

Author keywords

Cystic fibrosis; Initial P aeruginosa; Susceptibility

Indexed keywords

AMIKACIN; AZTREONAM; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TIMENTIN; TOBRAMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BROTH DILUTION; CHILD; CYSTIC FIBROSIS; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MIC50; MIC90; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT INFECTION; TREATMENT FAILURE; ADULT; COMPLICATION; DRUG EFFECTS; INFANT; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; PHYSIOLOGY; PRESCHOOL CHILD; PSEUDOMONAS INFECTIONS; TRANSMISSION; UNITED STATES;

ADULT; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; INFANT; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; UNITED STATES;

EID: 85006226149     PISSN: 20487193     EISSN: 20487207     Source Type: Journal    
DOI: 10.1093/jpids/pit052     Document Type: Article

References (11)

1. Langton Hewer SC, Smyth AR. Antibiotic strategies for eradicatingPseudomonas aeruginosa in people with cystic fibrosis.Cochrane Database Syst Rev 2009; Oct 7;(4):CD004197.
2. Ryan G, Singh M, Dwan K. Inhaled antibiotics for long-termtherapy in cystic fibrosis. Cochrane Database Syst Rev 2011;Mar 16;(3):CD001021.
3. Emerson J, McNamara S, Buccat AM, Worrell K, Burns JL.Changes in cystic fibrosis sputum microbiology in the UnitedStates between 1995 and 2008. Pediatr Pulmonol 2010; 45:363-70.
4. Cystic Fibrosis Foundation Patient Registry: 2011 Annual DataReport to the Center Directors. Bethesda, MD. 2012; CysticFibrosis Foundation.
5. Treggiari MM, Rosenfeld M, Mayer-Hamblett N, et al. Earlyanti-pseudomonal acquisition in young patients with cystic fibrosis:rationale and design of the EPIC clinical trial and observationalstudy. Contemp Clin Trials 2009; 30:256-68.
6. Clinical and Laboratory Standards Institute. PerformanceStandards for Antimicrobial Susceptibility Testing; 22ndInformational Supplement. CLSI document M100-S22. CLSI,Wayne, PA; 2012.
7. European Committee on Antimicrobial Susceptibility Testing(EUCAST). Antimicrobial wild type distributions of microorganisms.Available at: http://www.eucast.org/mic_distributions.Accessed August 28, 2013.
8. Smith AL, Fiel SB, Mayer-Hamblett N, et al. Susceptibilitytesting of Pseudomonas aeruginosa isolates and clinical responseto parenteral antibiotic administration: lack of association incystic fibrosis. Chest 2003; 123:1495-502.
9. Hurley MN, Ariff AH, Bertenshaw C, et al. Results of antibioticsusceptibility testing do not influence clinical outcome in childrenwith cystic fibrosis. J Cyst Fibros 2012; 11:288-92.
10. Konstan MW, VanDevanter DR, Rasouliyan L, et al. Trends inthe use of routine therapies in cystic fibrosis: 1995-2005. PediatrPulmonol 2010; 45:1167-72.
11. Cheng K, Smyth RL, Govan JR, et al. Spread of betalactam-resistant Pseudomonas aeruginosa in a cystic fibrosisclinic. Lancet 1996; 348:639-42.